Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.

Nuvation Bio Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, JULY 22, 2026 /PRNEWSWIRE/ -- NUVATION BIO INC. ("NUVATION BIO") (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON TACKLING SOME OF THE TOUGHEST CHALLENGES IN CANCER TREATMENT, TODAY ANNOUNCED IT WILL HOST A CONFERENCE CALL AND WEBCAST ON THURSDAY, AUGUST 6, 2026, AT 8:00 A.M. ET TO DISCUSS ITS FINANCIAL RESULTS AND BUSINESS UPDATES FOR THE SECOND QUARTER OF 2026.

NUVATION BIO TO REPORT SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON AUGUST 6, 2026

UPDATED DATA FROM PHASE 2 STUDY SHOW CONFIRMED OBJECTIVE RESPONSE RATE OF 52% AND 36-MONTH PROGRESSION-FREE SURVIVAL RATE OF 79% WITHNEARLY40MONTHSOF FOLLOW-UP NEW PHASE 3 STUDY TO EVALUATE SAFUSIDENIB IN NEWLY DIAGNOSED GRADE 2 GLIOMA PATIENTS OUTSIDE THE U.S. NEW PHASE 2 STUDY TO EVALUATE SAFUSIDENIB IN PATIENTS WHOSE GLIOMA HAS PROGRESSED FOLLOWING TREATMENT WITH VORASIDENIB IN U.S. NEW YORK, JULY 20, 2026 /PRNEWSWIRE/ -- NUVATION BIO INC. (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON TACKLING SOME OF THE TOUGHEST CHALLENGES IN CANCER TREATMENT, TODAY ANNOUNCED UPDATED POSITIVE LONG-TERM FOLLOW-UP DATA FROM THE PHASE 2 (J201) STUDY OF SAFUSIDENIB IN PATIENTS WITH CHEMOTHERAPY- AND RADIOTHERAPY-NAVEGRADE 2IDH1-MUTANT GLIOMA.WITH ANADDITIONALYEAR OF FOLLOW-UP,RESPONSES TOSAFUSIDENIBINCREASED AND FURTHERDEEPENED, AND ITS SAFETY PROFILE REMAINEDCONSISTENT AND MANAGEABLE.

NUVATION BIO ANNOUNCES POSITIVE UPDATED PHASE 2 DATA AND EXPANSION OF SAFUSIDENIB CLINICAL PROGRAM WITH TWO NEW STUDIES TO EXPLORE BROAD SPECTRUM OF IDH1-MUTANT GLIOMA

NEW YORK, JULY 6, 2026 /PRNEWSWIRE/ -- NUVATION BIO INC. ("NUVATION BIO") (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON TACKLING SOME OF THE TOUGHEST CHALLENGES IN CANCER TREATMENT, TODAY ANNOUNCED THAT THE UNDERWRITERS HAVE EXERCISED IN FULL THEIR OVER-ALLOTMENT OPTION (THE "GREENSHOE EXERCISE") TO PURCHASE AN ADDITIONAL $37.5 MILLION AGGREGATE PRINCIPAL AMOUNT OF ITS 0.75% CONVERTIBLE SENIOR NOTES DUE 2032 (THE "NOTES"). THE AGGREGATE PRINCIPAL AMOUNT OF NOTES SOLD IN THE OFFERING WAS $287.5 MILLION, INCLUSIVE OF THE $37.5 MILLION AGGREGATE PRINCIPAL AMOUNT OF NOTES ISSUED PURSUANT TO THE GREENSHOE EXERCISE.

NUVATION BIO INC. ANNOUNCES FULL EXERCISE OF GREENSHOE OPTION IN $287.5 MILLION CONVERTIBLE SENIOR NOTES OFFERING

FOR U.S. AUDIENCES ONLY. THIS PRESS RELEASE IS NOT FOR A U.K. AUDIENCE.

NUVATION BIO ANNOUNCES MARKETING AUTHORISATION APPLICATION FOR TALETRECTINIB FOR THE TREATMENT OF ADVANCED ROS1-POSITIVE NON-SMALL CELL LUNG CANCER VALIDATED IN THE UNITED KINGDOM

NEW YORK, JUNE 25, 2026 NUVATION BIO INC. ("NUVATION BIO") (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON TACKLING SOME OF THE TOUGHEST CHALLENGES IN CANCER TREATMENT, TODAY ANNOUNCED THE PRICING OF ITS UNDERWRITTEN OFFERING (THE "OFFERING") OF $250.0 MILLION AGGREGATE PRINCIPAL AMOUNT OF 0.75% CONVERTIBLE SENIOR NOTES DUE IN 2032 (THE "NOTES"). THE AGGREGATE PRINCIPAL AMOUNT OF THE OFFERING WAS INCREASED FROM THE PREVIOUSLY ANNOUNCED OFFERING SIZE OF $200.0 MILLION.

NUVATION BIO ANNOUNCES PRICING OF UPSIZED OFFERING OF $250.0 MILLION OF CONVERTIBLE SENIOR NOTES

NEW YORK, JUNE 25, 2026 /PRNEWSWIRE/ -- NUVATION BIO INC. ("NUVATION BIO") (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON TACKLING SOME OF THE TOUGHEST CHALLENGES IN CANCER TREATMENT, TODAY ANNOUNCED ITS INTENT TO OFFER, SUBJECT TO MARKET CONDITIONS AND OTHER FACTORS, $200.0 MILLION AGGREGATE PRINCIPAL AMOUNT OF CONVERTIBLE SENIOR NOTES DUE IN 2032 (THE "NOTES") IN AN UNDERWRITTEN OFFERING (THE "OFFERING"). NUVATION BIO ALSO INTENDS TO GRANT THE UNDERWRITERS OF THE NOTES A RIGHT TO PURCHASE, EXERCISABLE WITHIN 30 DAYS OF THE DATE OF THE PROSPECTUS SUPPLEMENT RELATING TO THE OFFERING, UP TO AN ADDITIONAL $30.0 MILLION AGGREGATE PRINCIPAL AMOUNT OF NOTES, SOLELY TO COVER OVER-ALLOTMENTS, IF ANY.

NUVATION BIO ANNOUNCES PROPOSED CONVERTIBLE SENIOR NOTES OFFERING

NEW YORK, MAY 27, 2026 /PRNEWSWIRE/ -- NUVATION BIO INC. (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON TACKLING SOME OF THE TOUGHEST CHALLENGES IN CANCER TREATMENT, TODAY ANNOUNCED THAT DAVID HUNG, M.D., FOUNDER, PRESIDENT, AND CHIEF EXECUTIVE OFFICER OF NUVATION BIO, AND PHILIPPE SAUVAGE, CHIEF FINANCIAL OFFICER OF NUVATION BIO, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE ON WEDNESDAY, JUNE 3, 2026, AT 9:55 A.M.

NUVATION BIO TO PRESENT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

88% OF TRUST-II PATIENTS REPORTED IMPROVED OR STABLE QUALITY OF LIFE AT FIRST ASSESSMENT, WITH THE MAJORITY SUSTAINING THAT BENEFIT THROUGHOUT TREATMENT COGNITIVE FUNCTION SCORES IMPROVED OR REMAINED STABLE THROUGHOUT THE COURSE OF TREATMENT WITH IBTROZI IBTROZI PROVIDED RAPID RELIEF FROM BURDENSOME SYMPTOMS, INCLUDING COUGH AND SHORTNESS OF BREATH NEW YORK, MAY 27, 2026 /PRNEWSWIRE/ -- NUVATION BIO INC. (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON TACKLING SOME OF THE TOUGHEST CHALLENGES IN CANCER TREATMENT, TODAY ANNOUNCED NEW PATIENT-REPORTED OUTCOMES DATA FROM THE PIVOTAL TRUST-II STUDY OF IBTROZI (TALETRECTINIB) IN PATIENTS WITH ADVANCED ROS1-POSITIVE (ROS1+) NON-SMALL CELL LUNG CANCER (NSCLC). THE NEW DATA WILL BE PRESENTED ON SUNDAY, MAY 31 AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING 2026.

NUVATION BIO TO PRESENT NEW QUALITY-OF-LIFE DATA FOR IBTROZI (TALETRECTINIB) IN PATIENTS WITH ROS1-POSITIVE NON-SMALL CELL LUNG CANCER AT ASCO 2026 ANNUAL MEETING

THERMO FISHER SCIENTIFIC, THE WORLD LEADER IN SERVING SCIENCE, WILL NOW MANUFACTURE DRUG PRODUCT FOR NUVATION BIO IN THE UNITED STATES MOVE BY NUVATION BIO FURTHER ENSURES CRITICAL DRUG SUPPLY FOR PATIENTS AND PROVIDERS NEW YORK, MAY 13, 2026 /PRNEWSWIRE/ -- NUVATION BIO INC. (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON TACKLING SOME OF THE TOUGHEST CHALLENGES IN CANCER TREATMENT, TODAY ANNOUNCED THE SUCCESSFUL COMPLETION OF PROCESS TECH TRANSFER AND PRODUCT INTRODUCTION TO THERMO FISHER SCIENTIFIC, THE WORLD LEADER IN SERVING SCIENCE, FOR IBTROZI (TALETRECTINIB) TO TREAT ADVANCED OR METASTATIC ROS1-POSITIVE (ROS1+) NON-SMALL CELL LUNG CANCER (NSCLC). THE TRANSITION WAS SUBMITTED AS A SUPPLEMENT TO THE IBTROZI NEW DRUG APPLICATION HELD BY NUVATION BIO AND IS NOW COMPLETE.

NUVATION BIO TO COLLABORATE WITH THERMO FISHER SCIENTIFIC FOR U.S.-BASED MANUFACTURING OF IBTROZI FOR ROS1-POSITIVE NON-SMALL CELL LUNG CANCER

APPLICATION INCLUDES UPDATED TRUST-I TKI-NAVE MEDIAN DURATION OF RESPONSE (MDOR) AND MEDIAN PROGRESSION-FREE SURVIVAL (MPFS) OF MORE THAN 4 YEARS, AS WELL AS TRUST-II TKI-PRETREATED MDOR OF NEARLY 20 MONTHS FDA HAS ASSIGNED A TARGET ACTION DATE OF JANUARY 4, 2027 NEW YORK, MAY 6, 2026 /PRNEWSWIRE/ -- NUVATION BIO INC. (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON TACKLING SOME OF THE TOUGHEST CHALLENGES IN CANCER TREATMENT, ANNOUNCED TODAY THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS ACCEPTED A SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) WITH UPDATED DATA FOR IBTROZI  (TALETRECTINIB) IN BOTH TKI-NAVE AND TKI-PRETREATED ADVANCED ROS1-POSITIVE (ROS1+) NON-SMALL CELL LUNG CANCER (NSCLC) WITH A TARGET ACTION DATE OF JANUARY 4, 2027. THE SUBMISSION, WHICH FULFILLS AN FDA POST-MARKETING COMMITMENT AND IS INTENDED TO UPDATE THE EFFICACY INFORMATION PROVIDED IN THE IBTROZI LABEL, INCLUDES AN ADDITIONAL 10 MONTHS OF DATA FROM THE PIVOTAL TRUST-I AND TRUST-II STUDIES AS OF AN AUGUST 2025 DATA CUTOFF, FURTHER VALIDATING THE OVERALL CLINICAL PROFILE WITH LONG-TERM FOLLOW-UP.

NUVATION BIO ANNOUNCES FDA ACCEPTANCE OF SUPPLEMENTAL NEW DRUG APPLICATION FOR IBTROZI (TALETRECTINIB) WITH UPDATED DURATION OF RESPONSE IN ADVANCED ROS1-POSITIVE NON-SMALL CELL LUNG CANCER

Nuvation Bio Inc.

NUVB

Price

Financial Reports

No items found.

Press Releases

Nuvation Bio Inc.

NUVB.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

NUVB